BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schmeichel BE, Barbier E, Misra KK, Contet C, Schlosburg JE, Grigoriadis D, Williams JP, Karlsson C, Pitcairn C, Heilig M, Koob GF, Vendruscolo LF. Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats. Neuropsychopharmacology 2015;40:1123-9. [PMID: 25367502 DOI: 10.1038/npp.2014.293] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Flores Á, Julià-Hernández M, Maldonado R, Berrendero F. Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9) -tetrahydrocannabinol. Br J Pharmacol 2016;173:1381-92. [PMID: 26799708 DOI: 10.1111/bph.13440] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
2 Fartootzadeh R, Azizi F, Alaei H, Reisi P. Orexin type-2 receptor blockade prevents the nicotine-induced excitation of nucleus accumbens core neurons in rats: An electrophysiological perspective. Pharmacol Rep 2019;71:361-6. [PMID: 30831442 DOI: 10.1016/j.pharep.2018.12.013] [Reference Citation Analysis]
3 Kimbrough A, Kononoff J, Simpson S, Kallupi M, Sedighim S, Palomino K, Conlisk D, Momper JD, de Guglielmo G, George O. Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats. Psychopharmacology (Berl) 2020;237:1545-55. [PMID: 32114633 DOI: 10.1007/s00213-020-05479-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
4 Flores Á, Saravia R, Maldonado R, Berrendero F. Orexins and fear: implications for the treatment of anxiety disorders. Trends in Neurosciences 2015;38:550-9. [DOI: 10.1016/j.tins.2015.06.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
5 James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology 2020;45:717-9. [PMID: 31986520 DOI: 10.1038/s41386-020-0619-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
6 Schmeichel BE, Matzeu A, Koebel P, Vendruscolo LF, Sidhu H, Shahryari R, Kieffer BL, Koob GF, Martin-Fardon R, Contet C. Knockdown of hypocretin attenuates extended access of cocaine self-administration in rats. Neuropsychopharmacology 2018;43:2373-82. [PMID: 29703996 DOI: 10.1038/s41386-018-0054-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
7 Koob GF, Schulkin J. Addiction and stress: An allostatic view. Neuroscience & Biobehavioral Reviews 2019;106:245-62. [DOI: 10.1016/j.neubiorev.2018.09.008] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 24.7] [Reference Citation Analysis]
8 Matzeu A, Martin-Fardon R. Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats. Neuropharmacology 2020;164:107906. [PMID: 31841797 DOI: 10.1016/j.neuropharm.2019.107906] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
9 Towers EB, Tunstall BJ, McCracken ML, Vendruscolo LF, Koob GF. Male and female mice develop escalation of heroin intake and dependence following extended access. Neuropharmacology 2019;151:189-94. [PMID: 30880124 DOI: 10.1016/j.neuropharm.2019.03.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
10 Matzeu A, Kerr TM, Weiss F, Martin-Fardon R. Orexin-A/Hypocretin-1 Mediates Cocaine-Seeking Behavior in the Posterior Paraventricular Nucleus of the Thalamus via Orexin/Hypocretin Receptor-2. J Pharmacol Exp Ther 2016;359:273-9. [PMID: 27540003 DOI: 10.1124/jpet.116.235945] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
11 Koob GF. Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction. Psychopharmacology (Berl) 2017;234:1315-32. [PMID: 28050629 DOI: 10.1007/s00213-016-4484-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
12 McGinn MA, Pantazis CB, Tunstall BJ, Marchette RCN, Carlson ER, Said N, Koob GF, Vendruscolo LF. Drug addiction co-morbidity with alcohol: Neurobiological insights. Int Rev Neurobiol 2021;157:409-72. [PMID: 33648675 DOI: 10.1016/bs.irn.2020.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
14 Rodríguez-Arias M, Aguilar MA, Miñarro J. Therapies in early development for the treatment of opiate addiction. Expert Opin Investig Drugs 2015;24:1459-72. [PMID: 26414784 DOI: 10.1517/13543784.2015.1086746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
15 Fragale JE, Pantazis CB, James MH, Aston-Jones G. The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacology 2019;44:1690-7. [PMID: 31112988 DOI: 10.1038/s41386-019-0420-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
16 [DOI: 10.1101/2020.04.25.061887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Matzeu A, Martin-Fardon R. Drug Seeking and Relapse: New Evidence of a Role for Orexin and Dynorphin Co-transmission in the Paraventricular Nucleus of the Thalamus. Front Neurol 2018;9:720. [PMID: 30210441 DOI: 10.3389/fneur.2018.00720] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
18 Fragale JE, James MH, Aston-Jones G. Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system. Addict Biol 2021;26:e12946. [PMID: 32798290 DOI: 10.1111/adb.12946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
19 Li SB, de Lecea L. The hypocretin (orexin) system: from a neural circuitry perspective. Neuropharmacology 2020;167:107993. [PMID: 32135427 DOI: 10.1016/j.neuropharm.2020.107993] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
20 Kwako LE, Koob GF. Neuroclinical Framework for the Role of Stress in Addiction. Chronic Stress (Thousand Oaks) 2017;1. [PMID: 28653044 DOI: 10.1177/2470547017698140] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
21 Zarrabian S, Riahi E, Karimi S, Razavi Y, Haghparast A. The potential role of the orexin reward system in future treatments for opioid drug abuse. Brain Research 2020;1731:146028. [DOI: 10.1016/j.brainres.2018.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
22 Khoo SY, Gibson GD, Prasad AA, McNally GP. How contexts promote and prevent relapse to drug seeking. Genes Brain Behav 2017;16:185-204. [PMID: 27612655 DOI: 10.1111/gbb.12328] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
23 Daiwile AP, Jayanthi S, Ladenheim B, McCoy MT, Brannock C, Schroeder J, Cadet JL. Sex Differences in Escalated Methamphetamine Self-Administration and Altered Gene Expression Associated With Incubation of Methamphetamine Seeking. Int J Neuropsychopharmacol 2019;22:710-23. [PMID: 31562746 DOI: 10.1093/ijnp/pyz050] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
24 Vendruscolo JCM, Tunstall BJ, Carmack SA, Schmeichel BE, Lowery-Gionta EG, Cole M, George O, Vandewater SA, Taffe MA, Koob GF, Vendruscolo LF. Compulsive-Like Sufentanil Vapor Self-Administration in Rats. Neuropsychopharmacology 2018;43:801-9. [PMID: 28812595 DOI: 10.1038/npp.2017.172] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
25 Lynch WJ. Modeling the development of drug addiction in male and female animals. Pharmacol Biochem Behav 2018;164:50-61. [PMID: 28624586 DOI: 10.1016/j.pbb.2017.06.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
26 Gentile TA, Simmons SJ, Barker DJ, Shaw JK, España RA, Muschamp JW. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Addict Biol 2018;23:247-55. [PMID: 28419646 DOI: 10.1111/adb.12507] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
27 Feltenstein MW, See RE, Fuchs RA. Neural Substrates and Circuits of Drug Addiction. Cold Spring Harb Perspect Med 2021;11:a039628. [PMID: 32205414 DOI: 10.1101/cshperspect.a039628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
28 Zlebnik NE, Holtz NA, Lepak VC, Saykao AT, Zhang Y, Carroll ME. Age-specific treatment effects of orexin/hypocretin-receptor antagonism on methamphetamine-seeking behavior. Drug Alcohol Depend 2021;224:108719. [PMID: 33940327 DOI: 10.1016/j.drugalcdep.2021.108719] [Reference Citation Analysis]
29 Fattore L, Diana M. Drug addiction: An affective-cognitive disorder in need of a cure. Neuroscience & Biobehavioral Reviews 2016;65:341-61. [DOI: 10.1016/j.neubiorev.2016.04.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
30 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
31 Simmons SJ, Gentile TA, Mo L, Tran FH, Ma S, Muschamp JW. Nicotinic receptor blockade decreases fos immunoreactivity within orexin/hypocretin-expressing neurons of nicotine-exposed rats. Behav Brain Res 2016;314:226-33. [PMID: 27491589 DOI: 10.1016/j.bbr.2016.07.053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
32 Matzeu A, Martin-fardon R. Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value. Front Behav Neurosci 2022;15:787595. [DOI: 10.3389/fnbeh.2021.787595] [Reference Citation Analysis]
33 Norwood VM 4th, Brice-Tutt AC, Eans SO, Stacy HM, Shi G, Ratnayake R, Rocca JR, Abboud KA, Li C, Luesch H, McLaughlin JP, Huigens RW 3rd. Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity. J Med Chem 2020;63:5119-38. [PMID: 31913038 DOI: 10.1021/acs.jmedchem.9b01924] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
34 Hopf FW. Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors. Neuropharmacology 2020;168:108013. [PMID: 32092435 DOI: 10.1016/j.neuropharm.2020.108013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
35 Brown RM, Dayas CV, James MH, Smith RJ. New directions in modelling dysregulated reward seeking for food and drugs. Neurosci Biobehav Rev 2021:S0149-7634(21)00485-1. [PMID: 34736883 DOI: 10.1016/j.neubiorev.2021.10.043] [Reference Citation Analysis]
36 Mason BJ. Emerging pharmacotherapies for alcohol use disorder. Neuropharmacology 2017;122:244-53. [PMID: 28454983 DOI: 10.1016/j.neuropharm.2017.04.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
37 James MH, Aston-Jones G. Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?". Brain Res 2020;1731:146665. [PMID: 31930996 DOI: 10.1016/j.brainres.2020.146665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]